Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma

Abstract

SYF2, also known as p29/NTC31/CBPIN, encodes a nuclear protein that interacts with Cyclin D-type binding-protein 1. SYF2 has been reported to be involved in pre-mRNA splicing and cell cycle regulation. In the present study, we observed that SYF2 was obviously upregulated in HCC tumor tissues and cell lines, and its level was positively correlated with the tumor grade and Ki-67 expression, as well as poor prognosis of HCC. In vitro, using serum starvation-refeeding experiment, our results suggested that SYF2 was upregulated in proliferating HCC cells, and was positive correlated with the expression of PCNA and Cyclin D1. In addition, depletion of SYF2 decreased PCNA and Cyclin D1 levels. Accordingly, interference of SYF2 resulted in cells cycle arrest at G1/S phase in Huh7 HCC cells. Furthermore, we found that SYF2 might interact with Cyclin D1 and could confer doxorubicin resistance in HCC cells. These findings revealed that SYF2 might play a regulatory role in the proliferation of HCC cells. In summary, SYF2 may be a novel prognostic marker and serve as a potential therapeutic target in HCC.

RETRACTED: Influence of miR-376c-3p/SYF2 Axis on the Progression of Gastric Cancer

“…17 Moreover, SYF2 was reported as indicator for the poor overall survival of patients with esophageal squamous cell carcinoma, breast cancer, or hepatocellular carcinoma. 15 -17 In this report, luciferase activity reporter assay showed miR-376c-3p could directly binding with the 3′-UTR of SYF2. Western blot assay shown that miR-376c-3p could negatively regulate the expression of SYF2.…”

“…15 Depletion of SYF2 decreased PCNA and cyclin D1 levels to decrease cell growth and cell cycle arrested. 16 Overexpression of SYF2 was also shown could promote breast cancer cell proliferation, while the knockdown of SYF2 led to the cell cycle arrest at G1/S phase. 17 Moreover, SYF2 was reported as indicator for the poor overall survival of patients with esophageal squamous cell carcinoma, breast cancer, or hepatocellular carcinoma.…”

Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer

“…Recent evidence implicates that SYF2 participates in progress of diverse tumor entities, such as liver cancer [ 21 ], ovarian cancer [ 22 ], lung cancer [ 23 ], and esophageal cancer [ 24 ]. However, the role of SYF2 in breast cancer development remains obscure.…”

“…As we have mentioned previously, SYF2 might play a pro-apoptotic role in neuronal apoptosis [ 14 ]. Additionally, it has been described that SYF2 can down-regulate the sensitivity of ESCC cells for cisplatin [ 24 ] and induce doxorubicin resistance in HCC cells [ 21 ]. Thus, SYF2 might have a similar impact on breast cancer cells.…”

Retinoblastoma Binding Protein 5 Correlates with the Progression in Hepatocellular Carcinoma

“…RBBP5 is required for H3K4 methylation, which is a common marker of transcriptional activity in tumors, such as leukemia [ 11 , 14 ]. In addition, many other RB1 interacting proteins or their cognate proteins such as SYF2 and Bog are involved in the HCC process [ 15 , 16 ]. However, the expression and precise role of RBBP5 in HCC remains virtually unknown.…”